Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 19/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085383 | 0.83 | HCRTR1 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL3093210 | 0.80 | HCRTR1 (0.66) | HCRTR1HCRTR2 | |
| SCHEMBL4319632 | 0.80 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL3084479 | 0.79 | HCRTR1 (0.76) | HCRTR1HCRTR2 | |
| SCHEMBL3095517 | 0.78 | HCRTR2 (0.69) | HCRTR1HCRTR2 | |
| SCHEMBL4307362 | 0.78 | HCRTR1 (0.69) | HCRTR1HCRTR2 | |
| SCHEMBL13703858 | 0.71 | HCRTR2 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL4310855 | 0.71 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL20827789 | 0.71 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL3086637 | 0.71 | HCRTR1 (0.65) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263586-B2 | OXO bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | claimed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | claimed |
| US-8263586-B2 | OXO bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263586-B2 | OXO bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263586-B2 | OXO bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | disclosed |
| WO-2008143856-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885CYP3A4 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.